Health Care

Insmed’s Q2 2026 earnings beat expectations thanks to Brinsupri’s strong sales, and its clinical data shows robust PAH benefits and promising TPIP results, boosting future growth forecasts.

Kyowa Kirin partners with Cognizant and Benchling to launch an AI‑powered drug‑discovery platform, speeding discovery, improving safety profiling, and cutting R&D costs.

SEC Form 4 reveals ELEVANCE HEALTH’s share gift to a trust, reducing owner influence while keeping board continuity—and highlights ELEV‑01’s promising 42% response rate.

United Therapeutics (UTHR) shares surge to 33.5% ownership after a 9,500‑option exercise and multi‑day sales—see the SEC 10(b)(5) filing that details the strategy and impact.

BDX’s CEO Thomas Polen’s new stock purchases, sales, and SAR vesting reveal a deeper executive stake in Becton, Dickinson’s future.

Sheena Jonathan’s 10b5‑1 share sale shows Natera’s strong governance and executive confidence, while highlighting market‑access, patent cliff risks and M&A growth prospects.

European markets dipped as Argenx fell, spotlighting biotech patent cliffs and payer pressure, while SAP’s cloud & AI focus shows tech resilience amid investor caution.

United Therapeutics insider trading: CEO Martine A. Rothblatt’s trust‑based trades show disciplined equity management, hinting at future pipeline milestones and investor confidence.

Sheena Jonathan sold 6,000 Natera shares under a Rule 10b‑5 plan, keeping prices stable and ownership unchanged—no shift in governance or market impact.

Boston Scientific stock shows a bullish “hockey‑stick” rebound after a 2026 guidance cut—strong Q2 earnings, insider buying and a growing MiRus program hint at upside potential.